The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma

IF 1.2 4区 医学 Q4 HEMATOLOGY
Abdullah Karakus , Ugur Hatipoglu , Yavuz Katircilar , Mehmet Ali Erkurt , Seda Yilmaz , Gulsum Akgun Cagliyan , Fahir Ozturk , Emine Hidayet , Sinan Demircioglu , Mustafa Koroglu , Ant Uzay , Abdulkadir Basturk , Suleyman Sami Karti , Ahmet Sarici , Servihan Unal , Mehmet Sinan Dal , Turgay Ulaş , Serdal Korkmaz , Fevzi Altuntas
{"title":"The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma","authors":"Abdullah Karakus ,&nbsp;Ugur Hatipoglu ,&nbsp;Yavuz Katircilar ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Seda Yilmaz ,&nbsp;Gulsum Akgun Cagliyan ,&nbsp;Fahir Ozturk ,&nbsp;Emine Hidayet ,&nbsp;Sinan Demircioglu ,&nbsp;Mustafa Koroglu ,&nbsp;Ant Uzay ,&nbsp;Abdulkadir Basturk ,&nbsp;Suleyman Sami Karti ,&nbsp;Ahmet Sarici ,&nbsp;Servihan Unal ,&nbsp;Mehmet Sinan Dal ,&nbsp;Turgay Ulaş ,&nbsp;Serdal Korkmaz ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2025.104183","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m<sup>2</sup> doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma.</div></div><div><h3>Material and methods</h3><div>This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m<sup>2</sup> between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m<sup>2</sup> treated patients, and group 2 represents 3 gr/m<sup>2</sup> dosing. These two groups then compared in terms of CD34<sup>+</sup> cell number collected by apheresis, apheresis days, peak peripheral blood CD34<sup>+</sup> value and rates of mobilization failures.</div></div><div><h3>Results</h3><div>Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00–28.90) vs 9.01 (5.00–14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648).</div></div><div><h3>Conclusion</h3><div>This study indicated the superior efficacy of 3 gr/m<sup>2</sup> dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104183"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S147305022500120X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m2 doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma.

Material and methods

This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m2 between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m2 treated patients, and group 2 represents 3 gr/m2 dosing. These two groups then compared in terms of CD34+ cell number collected by apheresis, apheresis days, peak peripheral blood CD34+ value and rates of mobilization failures.

Results

Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00–28.90) vs 9.01 (5.00–14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648).

Conclusion

This study indicated the superior efficacy of 3 gr/m2 dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.
不同剂量环磷酰胺对多发性骨髓瘤干细胞动员作用的比较
我们进行了一项多中心回顾性非随机研究,以阐明2和3 gr/m2剂量的环磷酰胺(Cy)对多发性骨髓瘤干细胞动员的作用。材料和方法本研究分析了2018年至2024年间接受2和3 gr/m2剂量的城市动员方案的169名成年患者。本研究纳入的所有患者年龄均在18岁及以上。患者分为两组;组1代表2 gr/m2的治疗患者,组2代表3 gr/m2的剂量。然后比较两组的单采收集的CD34+细胞数、单采天数、外周血CD34+峰值和动员失败率。结果高剂量Cy比低剂量Cy产生更多造血干细胞[10.00 (3.00-28.90)vs 9.01 (5.00-14.90), p = 0.002];而动员失败和采血天数在各组间具有可比性(p = 0.112和p = 0.648)。各组间获得足够干细胞所需的采空天数在统计学上相似(p = 0.648)。结论3 gr/m2剂量的Cy对干细胞产量有显著的促进作用。然而,低剂量不存在动员失败和延长采血时间的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
5.30%
发文量
181
审稿时长
42 days
期刊介绍: Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信